The first one, setmelanotide, was approved in 2020, and it is used in patients with POMC, PCSK1, or leptin receptor (LEPR) deficiencies, which result in insufficient activation of the MC4R and, consequently, cause excessive appetite and severe obesity developing in early childhood. Here, LEPR is linked to obesity due to melanocortin 4 receptor deficiency.